| Year |
Citation |
Score |
| 2019 |
Howell SB, Zhang H, Rice WG. A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas Blood. 134: 5477-5477. DOI: 10.1182/Blood-2019-130784 |
0.329 |
|
| 2019 |
Howell SB, Zhang H, Rice WG. A Phase 1a/b Dose Escalation Study of Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS Blood. 134: 5148-5148. DOI: 10.1182/Blood-2019-129685 |
0.333 |
|
| 2019 |
Tsai C, Zhang H, Rice WG, Howell SB. Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations Blood. 134: 5755-5755. DOI: 10.1182/Blood-2019-123571 |
0.394 |
|
| 2019 |
Local A, Tsai C, Zhang H, Sheng S, Benbatoul K, Howell SB, Rice WG. Abstract 2096: Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in malignant B cells Cancer Research. 79: 2096-2096. DOI: 10.1158/1538-7445.Sabcs18-2096 |
0.438 |
|
| 2018 |
Local A, Zhang H, Benbatoul KD, Folger P, Sheng X, Tsai CY, Howell SB, Rice WG. APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells. Molecular Cancer Therapeutics. 17: 1177-1186. PMID 29626127 DOI: 10.1158/1535-7163.Mct-17-1209 |
0.309 |
|
| 2018 |
Tsai CY, Sun S, Zhang H, Local A, Su Y, Gross LA, Rice WG, Howell SB. APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency. Molecular Cancer Therapeutics. 17: 1167-1176. PMID 29626126 DOI: 10.1158/1535-7163.Mct-17-0834 |
0.419 |
|
| 2018 |
Schindler AJ, Watanabe A, Howell SB. LGR5 and LGR6 in stem cell biology and ovarian cancer. Oncotarget. 9: 1346-1355. PMID 29416699 DOI: 10.18632/Oncotarget.20178 |
0.328 |
|
| 2018 |
Zhang H, Local A, Benbatoul K, Folger P, Sheng S, Tsai C, Howell SB, Rice WG. Abstract 794: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro Cancer Research. 78: 794-794. DOI: 10.1158/1538-7445.Am2018-794 |
0.371 |
|
| 2017 |
Kurtz SE, Wilmot B, McWeeney S, Vellanki A, Local A, Benbatoul K, Folger P, Sheng S, Zhang H, Howell SB, Rice WG, Druker BJ, Tyner JW. Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes Clinical Cancer Research. 23: 44-44. DOI: 10.1158/1557-3265.Hemmal17-44 |
0.356 |
|
| 2017 |
Zhang W, Zhang H, Local A, Rice WG, Ly CJ, Yu G, Howell SB, Andreeff M. Abstract 25: CG′806, a first-in-class FLT3/BTK inhibitor, exerts superior potency against AML cells harboring ITD, TKD and gatekeeper mutated FLT3 or wild-type FLT3 Clinical Cancer Research. 23: 25-25. DOI: 10.1158/1557-3265.Hemmal17-25 |
0.31 |
|
| 2016 |
Bompiani KM, Tsai CY, Achatz FP, Liebig JK, Howell SB. Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Metallomics : Integrated Biometal Science. 8: 951-62. PMID 27157188 DOI: 10.1039/C6Mt00076B |
0.509 |
|
| 2016 |
Tsai C, Zhang H, Local A, Rice WG, Howell SB. Mechanisms of Resistance to Apto-253 Blood. 128: 5247-5247. DOI: 10.1182/Blood.V128.22.5247.5247 |
0.394 |
|
| 2015 |
Tsai CY, Liebig JK, Tsigelny IF, Howell SB. The copper transporter 1 (CTR1) is required to maintain the stability of copper transporter 2 (CTR2). Metallomics : Integrated Biometal Science. 7: 1477-87. PMID 26205368 DOI: 10.1039/C5Mt00131E |
0.477 |
|
| 2015 |
Yamamoto T, Tsigelny IF, Götz AW, Howell SB. Cisplatin inhibits MEK1/2. Oncotarget. 6: 23510-22. PMID 26155939 DOI: 10.18632/Oncotarget.4355 |
0.349 |
|
| 2015 |
Rice WG, Lightfoot J, Zhang H, Cheng T, Vellanki A, Peralta R, Howell SB, Local A, Chau F, Esquivies L. Clinical Pharmacokinetics of Apto-253 Support Its Use As a Novel Agent for the Treatment of Relapsed or Refractory Hematologic Malignancies Blood. 126: 4934-4934. DOI: 10.1182/Blood.V126.23.4934.4934 |
0.394 |
|
| 2015 |
Kurtz SE, Bottomly D, Wilmot B, McWeeney SK, Rice W, Howell SB, Vellanki A, Druker BJ, Tyner JW. Broad Activity of Apto-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level Blood. 126: 1358-1358. DOI: 10.1182/Blood.V126.23.1358.1358 |
0.319 |
|
| 2015 |
Shang X, Lin X, Howell SB. Abstract POSTER-BIOL-1318: Claudin 4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1318 |
0.307 |
|
| 2014 |
Wang Y, Ma J, Shen H, Wang C, Sun Y, Howell SB, Lin X. Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway. Oncology Reports. 32: 2150-8. PMID 25174950 DOI: 10.3892/Or.2014.3448 |
0.333 |
|
| 2014 |
Tsai CY, Larson CA, Safaei R, Howell SB. Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4. Biochemical Pharmacology. 90: 379-87. PMID 24967972 DOI: 10.1016/J.Bcp.2014.06.019 |
0.427 |
|
| 2014 |
Huang CP, Fofana M, Chan J, Chang CJ, Howell SB. Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics : Integrated Biometal Science. 6: 654-61. PMID 24522273 DOI: 10.1039/C3Mt00331K |
0.447 |
|
| 2014 |
Abada PB, Howell SB. Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. Plos One. 9: e87444. PMID 24475288 DOI: 10.1371/Journal.Pone.0087444 |
0.452 |
|
| 2014 |
Quail JF, Tsai CY, Howell SB. Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1). Journal of Trace Elements in Medicine and Biology : Organ of the Society For Minerals and Trace Elements (Gms). 28: 151-9. PMID 24447817 DOI: 10.1016/J.Jtemb.2013.12.003 |
0.355 |
|
| 2013 |
Lin X, Shang X, Manorek G, Howell SB. Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4. Plos One. 8: e67496. PMID 23805314 DOI: 10.1371/Journal.Pone.0067496 |
0.397 |
|
| 2013 |
Safaei R, Adams PL, Mathews RA, Manorek G, Howell SB. The role of metal binding and phosphorylation domains in the regulation of cisplatin-induced trafficking of ATP7B. Metallomics : Integrated Biometal Science. 5: 964-72. PMID 23803742 DOI: 10.1039/C3Mt00131H |
0.396 |
|
| 2013 |
Shang X, Lin X, Manorek G, Howell SB. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Molecular Pharmacology. 83: 85-94. PMID 23053666 DOI: 10.1124/Mol.112.079798 |
0.552 |
|
| 2013 |
Zhang S, Lai H, Liu G, Rassenti L, Choi MY, Howell SB, Finlayson M, Kipps TJ. A6 Peptide Is Selectively Cytotoxic For Chronic Lymphocytic Leukemia Cells Blood. 122: 5303-5303. DOI: 10.1182/Blood.V122.21.5303.5303 |
0.329 |
|
| 2012 |
Shang X, Lin X, Alvarez E, Manorek G, Howell SB. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia (New York, N.Y.). 14: 974-85. PMID 23097631 DOI: 10.1593/Neo.12942 |
0.337 |
|
| 2012 |
Tsai CY, Finley JC, Ali SS, Patel HH, Howell SB. Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling. Biochemical Pharmacology. 84: 1007-13. PMID 22842628 DOI: 10.1016/J.Bcp.2012.07.014 |
0.42 |
|
| 2012 |
Abada PB, Larson CA, Manorek G, Adams P, Howell SB. Sec61β controls sensitivity to platinum-containing chemotherapeutic agents through modulation of the copper-transporting ATPase ATP7A. Molecular Pharmacology. 82: 510-20. PMID 22710939 DOI: 10.1124/Mol.112.079822 |
0.531 |
|
| 2012 |
Tsigelny IF, Sharikov Y, Greenberg JP, Miller MA, Kouznetsova VL, Larson CA, Howell SB. An all-atom model of the structure of human copper transporter 1. Cell Biochemistry and Biophysics. 63: 223-34. PMID 22569840 DOI: 10.1007/S12013-012-9358-X |
0.376 |
|
| 2012 |
Safaei R, Adams PL, Maktabi MH, Mathews RA, Howell SB. The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin. Journal of Inorganic Biochemistry. 110: 8-17. PMID 22459168 DOI: 10.1016/J.Jinorgbio.2012.02.016 |
0.392 |
|
| 2012 |
Aebi S, Christen R, Naredi P, Cenni B, Fink D, Heath D, Howell S. Synergy between cisplatin and an inhibitor of S-adenosylmethionine dependent transmethylation in human ovarian adenocarcinoma cells. International Journal of Oncology. 11: 869-74. PMID 21528287 DOI: 10.3892/Ijo.11.4.869 |
0.451 |
|
| 2012 |
Fink D, Nebel S, Aebi S, Nehme A, Howell S. Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin. International Journal of Oncology. 11: 539-42. PMID 21528244 DOI: 10.3892/Ijo.11.3.539 |
0.423 |
|
| 2012 |
Mathews RA, Safaei R, Howell SB. Abstract 837: Copper efflux transporter-mediated resistance to cisplatin Cancer Research. 72: 837-837. DOI: 10.1158/1538-7445.Am2012-837 |
0.53 |
|
| 2011 |
Park JS, Kinsella JM, Jandial DD, Howell SB, Sailor MJ. Cisplatin-loaded porous Si microparticles capped by electroless deposition of platinum. Small (Weinheim An Der Bergstrasse, Germany). 7: 2061-9. PMID 21630444 DOI: 10.1002/Smll.201100438 |
0.314 |
|
| 2011 |
Kanatani I, Lin X, Yuan X, Manorek G, Shang X, Cheung LH, Rosenblum MG, Howell SB. Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin. Cancer Chemotherapy and Pharmacology. 68: 979-90. PMID 21327682 DOI: 10.1007/S00280-011-1573-4 |
0.301 |
|
| 2011 |
Yuan X, Lin X, Manorek G, Howell SB. Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency. Bmc Cancer. 11: 61. PMID 21303546 DOI: 10.1186/1471-2407-11-61 |
0.383 |
|
| 2011 |
Blair BG, Larson CA, Adams PL, Abada PB, Pesce CE, Safaei R, Howell SB. Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Molecular Pharmacology. 79: 157-66. PMID 20930109 DOI: 10.1124/Mol.110.068411 |
0.763 |
|
| 2011 |
Lin X, Yuan X, Manorek G, Howell SB. Abstract 3627: Targeted delivery of gelonin to claudin-expressing cancer cells and use of activatable cell penetrating peptides to enhance potency Cancer Research. 71: 3627-3627. DOI: 10.1158/1538-7445.Am2011-3627 |
0.311 |
|
| 2011 |
Abada PB, Howell SB. Abstract 1696: Regulation of sensitivity to the platinum-containing drugs by the sec61 translocon Cancer Research. 71: 1696-1696. DOI: 10.1158/1538-7445.Am2011-1696 |
0.497 |
|
| 2011 |
Lin X, Shang X, Manorek G, Howell SB. Abstract 1554: Claudin 3 (CLDN3) and claudin 4 (CLDN4) control the growth rate of human ovarian cancer cells in vivo Cancer Research. 71: 1554-1554. DOI: 10.1158/1538-7445.Am2011-1554 |
0.351 |
|
| 2010 |
Abada P, Howell SB. Regulation of Cisplatin cytotoxicity by cu influx transporters. Metal-Based Drugs. 2010: 317581. PMID 21274436 DOI: 10.1155/2010/317581 |
0.451 |
|
| 2010 |
Van S, Das SK, Wang X, Feng Z, Jin Y, Hou Z, Chen F, Pham A, Jiang N, Howell SB, Yu L. Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate. International Journal of Nanomedicine. 5: 825-37. PMID 21042550 DOI: 10.2147/Ijn.S13482 |
0.305 |
|
| 2010 |
Larson CA, Adams PL, Blair BG, Safaei R, Howell SB. The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Molecular Pharmacology. 78: 333-9. PMID 20519567 DOI: 10.1124/Mol.110.064766 |
0.775 |
|
| 2010 |
Larson CA, Adams PL, Jandial DD, Blair BG, Safaei R, Howell SB. The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Biochemical Pharmacology. 80: 448-54. PMID 20451502 DOI: 10.1016/J.Bcp.2010.04.030 |
0.757 |
|
| 2010 |
Blair BG, Larson CA, Adams PL, Abada PB, Safaei R, Howell SB. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Molecular Pharmacology. 77: 912-21. PMID 20194531 DOI: 10.1124/Mol.109.062836 |
0.784 |
|
| 2010 |
Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Molecular Pharmacology. 77: 887-94. PMID 20159940 DOI: 10.1124/Mol.109.063172 |
0.456 |
|
| 2010 |
Beretta GL, Benedetti V, Cossa G, Assaraf YG, Bram E, Gatti L, Corna E, Carenini N, Colangelo D, Howell SB, Zunino F, Perego P. Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochemical Pharmacology. 79: 1108-17. PMID 20005867 DOI: 10.1016/j.bcp.2009.12.002 |
0.361 |
|
| 2010 |
Damaj BB, Incardonna F, Piotrowicz R, Howell SB, Finlayson M. Abstract 5120: A6 peptide binds to CD44 and inhibits migration and metastasis of CD44+ cell lines inin vitroandin vivostudies Cancer Research. 70: 5120-5120. DOI: 10.1158/1538-7445.Am10-5120 |
0.317 |
|
| 2010 |
Larson CA, Adams PL, Jandial DD, Blair BG, Safaei R, Howell SB. Corrigendum to " The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin" [Biochem. Pharmacol. 80 (2010) 448-454] Biochemical Pharmacology. 80: 1768. DOI: 10.1016/J.Bcp.2010.08.006 |
0.749 |
|
| 2009 |
Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, Howell SB. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Molecular Cancer Therapeutics. 8: 1906-15. PMID 19567823 DOI: 10.1158/1535-7163.Mct-09-0106 |
0.347 |
|
| 2009 |
Blair BG, Larson CA, Safaei R, Howell SB. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4312-21. PMID 19509135 DOI: 10.1158/1078-0432.Ccr-09-0311 |
0.771 |
|
| 2009 |
Jandial DD, Farshchi-Heydari S, Larson CA, Elliott GI, Wrasidlo WJ, Howell SB. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 553-60. PMID 19147760 DOI: 10.1158/1078-0432.CCR-08-2081 |
0.401 |
|
| 2009 |
Safaei R, Maktabi MH, Blair BG, Larson CA, Howell SB. Effects of the loss of Atox1 on the cellular pharmacology of cisplatin. Journal of Inorganic Biochemistry. 103: 333-41. PMID 19124158 DOI: 10.1016/J.Jinorgbio.2008.11.012 |
0.756 |
|
| 2009 |
Larson CA, Blair BG, Safaei R, Howell SB. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Molecular Pharmacology. 75: 324-30. PMID 18996970 DOI: 10.1124/Mol.108.052381 |
0.773 |
|
| 2008 |
Kowalski D, Pendyala L, Daignan-Fornier B, Howell SB, Huang RY. Dysregulation of purine nucleotide biosynthesis pathways modulates cisplatin cytotoxicity in Saccharomyces cerevisiae. Molecular Pharmacology. 74: 1092-100. PMID 18612078 DOI: 10.1124/Mol.108.048256 |
0.428 |
|
| 2008 |
Safaei R, Otani S, Larson BJ, Rasmussen ML, Howell SB. Transport of cisplatin by the copper efflux transporter ATP7B. Molecular Pharmacology. 73: 461-8. PMID 17978167 DOI: 10.1124/mol.107.040980 |
0.337 |
|
| 2007 |
Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemotherapy and Pharmacology. 59: 301-12. PMID 16770583 DOI: 10.1007/S00280-006-0271-0 |
0.677 |
|
| 2006 |
Holzer AK, Howell SB. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Research. 66: 10944-52. PMID 17108132 DOI: 10.1158/0008-5472.Can-06-1710 |
0.802 |
|
| 2006 |
Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Molecular Pharmacology. 70: 1390-4. PMID 16847145 DOI: 10.1124/Mol.106.022624 |
0.792 |
|
| 2006 |
Lin X, Howell SB. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Molecular Cancer Therapeutics. 5: 1239-47. PMID 16731756 DOI: 10.1158/1535-7163.Mct-05-0491 |
0.417 |
|
| 2006 |
Holzer AK, Varki NM, Le QT, Gibson MA, Naredi P, Howell SB. Expression of the human copper influx transporter 1 in normal and malignant human tissues. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 54: 1041-9. PMID 16709730 DOI: 10.1369/Jhc.6A6970.2006 |
0.776 |
|
| 2006 |
Lin X, Okuda T, Trang J, Howell SB. Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells. Molecular Pharmacology. 69: 1748-54. PMID 16495473 DOI: 10.1124/Mol.105.020446 |
0.468 |
|
| 2006 |
Lin X, Trang J, Okuda T, Howell SB. DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 563-8. PMID 16428501 DOI: 10.1158/1078-0432.Ccr-05-1380 |
0.432 |
|
| 2006 |
Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemotherapy and Pharmacology. 58: 384-95. PMID 16404635 DOI: 10.1007/S00280-005-0171-8 |
0.695 |
|
| 2006 |
Samimi G, Howell SB. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemotherapy and Pharmacology. 57: 781-8. PMID 16170571 DOI: 10.1007/S00280-005-0121-5 |
0.762 |
|
| 2005 |
Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, Howell SB. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Molecular Cancer Therapeutics. 4: 1595-604. PMID 16227410 DOI: 10.1158/1535-7163.Mct-05-0102 |
0.484 |
|
| 2005 |
Okuda T, Lin X, Trang J, Howell SB. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Molecular Pharmacology. 67: 1852-60. PMID 15758147 DOI: 10.1124/Mol.104.010579 |
0.456 |
|
| 2005 |
Safaei R, Katano K, Larson BJ, Samimi G, Holzer AK, Naerdemann W, Tomioka M, Goodman M, Howell SB. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 756-67. PMID 15701866 |
0.789 |
|
| 2005 |
Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Critical Reviews in Oncology/Hematology. 53: 13-23. PMID 15607932 DOI: 10.1016/J.Critrevonc.2004.09.007 |
0.491 |
|
| 2005 |
Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G, Howell SB. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemotherapy and Pharmacology. 55: 1-11. PMID 15378272 DOI: 10.1007/s00280-004-0819-9 |
0.638 |
|
| 2004 |
Wu F, Lin X, Okuda T, Howell SB. DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Research. 64: 8029-35. PMID 15520212 DOI: 10.1158/0008-5472.Can-03-3942 |
0.411 |
|
| 2004 |
Holzer AK, Katano K, Klomp LW, Howell SB. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6744-9. PMID 15475465 DOI: 10.1158/1078-0432.Ccr-04-0748 |
0.818 |
|
| 2004 |
Safaei R, Holzer AK, Katano K, Samimi G, Howell SB. The role of copper transporters in the development of resistance to Pt drugs. Journal of Inorganic Biochemistry. 98: 1607-13. PMID 15458823 DOI: 10.1016/J.Jinorgbio.2004.05.006 |
0.814 |
|
| 2004 |
Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4661-9. PMID 15269138 DOI: 10.1158/1078-0432.Ccr-04-0137 |
0.824 |
|
| 2004 |
Katano K, Safaei R, Samimi G, Holzer A, Tomioka M, Goodman M, Howell SB. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4578-88. PMID 15240550 DOI: 10.1158/1078-0432.Ccr-03-0689 |
0.833 |
|
| 2004 |
Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Molecular Pharmacology. 66: 817-23. PMID 15229296 DOI: 10.1124/Mol.104.001198 |
0.83 |
|
| 2004 |
Samimi G, Katano K, Holzer AK, Safaei R, Howell SB. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Molecular Pharmacology. 66: 25-32. PMID 15213293 DOI: 10.1124/Mol.66.1.25 |
0.828 |
|
| 2004 |
Lin X, Zhang Q, Rice JR, Stewart DR, Nowotnik DP, Howell SB. Improved targeting of platinum chemotherapeutics: The antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models European Journal of Cancer. 40: 291-297. PMID 14728945 DOI: 10.1016/J.Ejca.2003.09.022 |
0.318 |
|
| 2004 |
Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M, Howell SB. Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemotherapy and Pharmacology. 53: 239-46. PMID 14648017 DOI: 10.1007/S00280-003-0736-3 |
0.706 |
|
| 2003 |
Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5853-9. PMID 14676106 |
0.716 |
|
| 2003 |
Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Molecular Pharmacology. 64: 466-73. PMID 12869652 DOI: 10.1124/Mol.64.2.466 |
0.831 |
|
| 2002 |
Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Research. 62: 6559-65. PMID 12438251 |
0.824 |
|
| 2002 |
de las Alas MM, Los G, Lin X, Kurdi-Haidar B, Manorek G, Howell SB. Identification of transdominant-negative genetic suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanine. Molecular Pharmacology. 62: 1198-206. PMID 12391284 DOI: 10.1124/Mol.62.5.1198 |
0.341 |
|
| 2002 |
Lin X, Okuda T, Holzer A, Howell SB. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Molecular Pharmacology. 62: 1154-9. PMID 12391279 DOI: 10.1124/Mol.62.5.1154 |
0.81 |
|
| 2002 |
Mishima M, Samimi G, Kondo A, Lin X, Howell SB. The cellular pharmacology of oxaliplatin resistance. European Journal of Cancer (Oxford, England : 1990). 38: 1405-12. PMID 12091073 DOI: 10.1016/S0959-8049(02)00096-5 |
0.716 |
|
| 2001 |
Niedner H, Christen R, Lin X, Kondo A, Howell SB. Identification of genes that mediate sensitivity to cisplatin. Molecular Pharmacology. 60: 1153-60. PMID 11723219 DOI: 10.1124/Mol.60.6.1153 |
0.4 |
|
| 2001 |
Kondo A, Safaei R, Mishima M, Niedner H, Lin X, Howell SB. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Research. 61: 7603-7. PMID 11606400 |
0.311 |
|
| 2001 |
Bergoglio V, Canitrot Y, Hogarth L, Minto L, Howell SB, Cazaux C, Hoffmann JS. Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene. 20: 6181-7. PMID 11593426 DOI: 10.1038/Sj.Onc.1204743 |
0.372 |
|
| 2001 |
Lin X, Gately DP, Hom D, Mishima M, Los G, Howell SB. Quantification of tumor cell injury in vitro and in vivo using expression of green fluorescent protein under the control of the GADD153 promoter. International Journal of Cancer. 91: 555-62. PMID 11251981 DOI: 10.1002/1097-0215(200002)9999:9999<::Aid-Ijc1083>3.0.Co;2-Q |
0.372 |
|
| 2000 |
Johnsson A, Zeelenberg I, Min Y, Hilinski J, Berry C, Howell SB, Los G. Identification of genes differentially expressed in association with acquired cisplatin resistance. British Journal of Cancer. 83: 1047-54. PMID 10993653 DOI: 10.1054/Bjoc.2000.1420 |
0.376 |
|
| 2000 |
Li H, Jiang X, Howell SB, Goodman M. Synthesis, conformational analysis and bioactivity of Lan-7, a lanthionine analog of TT-232 Journal of Peptide Science. 6: 26-35. PMID 10674717 DOI: 10.1002/(Sici)1099-1387(200001)6:1<26::Aid-Psc231>3.0.Co;2-6 |
0.346 |
|
| 2000 |
Isonishi S, Ohkawa K, Tanaka T, Howell SB. Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells. British Journal of Cancer. 82: 34-8. PMID 10638963 DOI: 10.1054/bjoc.1999.0873 |
0.34 |
|
| 2000 |
Chang DK, Goel A, Ricciardiello L, Lee D, Chang CL, Carethers JM, Howell SB, Richard Boland C. Hydrogen peroxide induces G2/M cell cycle arrest regardless of DNA mismatch repair (MMR) status, and is more lethal to MMR deficient cells Gastroenterology. 118: A856. DOI: 10.1016/S0016-5085(00)85567-5 |
0.316 |
|
| 1999 |
Lin X, Kim HK, Howell SB. The role of DNA mismatch repair in cisplatin mutagenicity. Journal of Inorganic Biochemistry. 77: 89-93. PMID 10626359 DOI: 10.1016/S0162-0134(99)00134-8 |
0.36 |
|
| 1999 |
Lin X, Howell SB. Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin. Molecular Pharmacology. 56: 390-5. PMID 10419559 DOI: 10.1124/Mol.56.2.390 |
0.471 |
|
| 1999 |
Nehmé A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY, Christen RD. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells. British Journal of Cancer. 79: 1104-10. PMID 10098743 DOI: 10.1038/Sj.Bjc.6690176 |
0.318 |
|
| 1999 |
Ferry KV, Fink D, Johnson SW, Nebel S, Hamilton TC, Howell SB. Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells. Biochemical Pharmacology. 57: 861-7. PMID 10086318 DOI: 10.1016/S0006-2952(98)00366-9 |
0.307 |
|
| 1998 |
Kurdi-Haidar B, Hom DK, Flittner DE, Heath D, Fink L, Naredi P, Howell SB. Dual cytoplasmic and nuclear distribution of the novel arsenite- stimulated human ATPase (hASNA-I) Journal of Cellular Biochemistry. 71: 1-10. PMID 9736449 DOI: 10.1002/(Sici)1097-4644(19981001)71:1<1::Aid-Jcb1>3.0.Co;2-# |
0.332 |
|
| 1998 |
Kurdi-Haidar B, Heath D, Aebi S, Howell SB. Biochemical characterization of the human arsenite-stimulated ATPase (hASNA-I). The Journal of Biological Chemistry. 273: 22173-6. PMID 9712828 DOI: 10.1074/Jbc.273.35.22173 |
0.305 |
|
| 1998 |
Fink D, Nebel S, Norris PS, Baergen RN, Wilczynski SP, Costa MJ, Haas M, Cannistra SA, Howell SB. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin International Journal of Cancer. 77: 741-746. PMID 9688308 DOI: 10.1002/(Sici)1097-0215(19980831)77:5<741::Aid-Ijc13>3.0.Co;2-4 |
0.454 |
|
| 1998 |
Perego P, Zunino F, Carenini N, Giuliani F, Spinelli S, Howell SB. Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants. Molecular Pharmacology. 54: 213-9. PMID 9658208 DOI: 10.1124/Mol.54.1.213 |
0.334 |
|
| 1998 |
Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 4: 1-6. PMID 9516945 |
0.329 |
|
| 1998 |
Fink D, Nebel S, Norris PS, Aebi S, Kim HK, Haas M, Howell SB. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. British Journal of Cancer. 77: 703-8. PMID 9514047 DOI: 10.1038/Bjc.1998.116 |
0.392 |
|
| 1997 |
Zheng H, Fink D, Howell SB. Pharmacological basis for a novel therapeutic strategy based on the use of aquated cisplatin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 3: 1157-65. PMID 9815795 |
0.308 |
|
| 1997 |
Aebi S, Kröning R, Cenni B, Sharma A, Fink D, Los G, Weisman R, Howell SB, Christen RD. all-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 3: 2033-8. PMID 9815594 |
0.329 |
|
| 1997 |
de las Alas MM, Aebi S, Fink D, Howell SB, Los G. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. Journal of the National Cancer Institute. 89: 1537-41. PMID 9337351 DOI: 10.1093/Jnci/89.20.1537 |
0.408 |
|
| 1997 |
Lindnér PG, Heath D, Howell SB, Naredi PL, Hafström LR. Digitonin enhances the efficacy of carboplatin in liver tumour after intra-arterial administration Cancer Chemotherapy and Pharmacology. 40: 444-448. PMID 9272123 DOI: 10.1007/S002800050684 |
0.331 |
|
| 1997 |
Wasenius VM, Jekunen A, Monni O, Joensuu H, Aebi S, Howell SB, Knuutila S. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes, Chromosomes & Cancer. 18: 286-91. PMID 9087568 DOI: 10.1002/(Sici)1098-2264(199704)18:4<286::Aid-Gcc6>3.0.Co;2-X |
0.34 |
|
| 1997 |
McClay EF, McClay ME, Jones JA, Winski PJ, Christen RD, Howell SB, Hall PD. A phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Cancer. 79: 1037-43. PMID 9041168 DOI: 10.1002/(Sici)1097-0142(19970301)79:5<1037::Aid-Cncr22>3.0.Co;2-1 |
0.304 |
|
| 1996 |
Kurdi-Haidar B, Aebi S, Heath D, Enns RE, Naredi P, Hom DK, Howell SB. Isolation of the ATP-binding human homolog of the arsA component of the bacterial arsenite transporter Genomics. 36: 486-491. PMID 8884272 DOI: 10.1006/Geno.1996.0494 |
0.349 |
|
| 1996 |
McClay EF, Jones JA, Winski PJ, Albright KD, Christen RD, Howell SB. Determinants of tamoxifen sensitivity control the nature of the aynergistic interaction between tamoxifen and cisplatin Cancer Research. 56: 3993-3997. PMID 8752169 |
0.33 |
|
| 1996 |
Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Research. 56: 3087-90. PMID 8674066 |
0.328 |
|
| 1996 |
Gately DP, Sharma A, Christen RD, Howell SB. Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153. British Journal of Cancer. 73: 18-23. PMID 8554977 DOI: 10.1038/Bjc.1996.4 |
0.346 |
|
| 1996 |
Robbins KT, Storniolo AM, Hryniuk WM, Howell SB. "Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. II. Clinical studies. The Laryngoscope. 106: 37-42. PMID 8544625 DOI: 10.1097/00005537-199601000-00008 |
0.392 |
|
| 1996 |
Los G, Blommaert fA, Barton R, Heath DD, den Engelse L, Hanchett C, Vicario D, Weisman R, Robbins KT, Howell SB. Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Cancer Chemotherapy and Pharmacology. 37: 150-4. PMID 7497585 DOI: 10.1007/Bf00685642 |
0.317 |
|
| 1995 |
Gately DP, Jones JA, Christen R, Barton RM, Los G, Howell SB. Induction of the growth arrest and DNA damage-inducible gene GADD153 by cisplatin in vitro and in vivo. British Journal of Cancer. 70: 1102-6. PMID 7981060 DOI: 10.1038/Bjc.1994.455 |
0.365 |
|
| 1995 |
Naredi P, Heath DD, Enns RE, Howell SB. Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells Journal of Clinical Investigation. 95: 1193-1198. PMID 7883968 DOI: 10.1172/Jci117768 |
0.409 |
|
| 1995 |
Nakata B, Albright KD, Barton RM, Howell SB, Los G. Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines Cancer Chemotherapy and Pharmacology. 35: 511-518. PMID 7882460 DOI: 10.1007/Bf00686837 |
0.417 |
|
| 1995 |
Kröning R, Jones JA, Hom DK, Chuang CC, Sanga R, Los G, Howell SB, Christen RD. Enhancement of drug sensitivity of human malignancies by epidermal growth factor. British Journal of Cancer. 72: 615-9. PMID 7669570 DOI: 10.1038/Bjc.1995.382 |
0.445 |
|
| 1994 |
Isonishi S, Hom DK, Eastman A, Howell SB. Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line. British Journal of Cancer. 69: 217-21. PMID 8297717 DOI: 10.1038/Bjc.1994.42 |
0.399 |
|
| 1994 |
McClay EF, Albright KD, Jones JA, Christen RD, Howell SB. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. International Journal of Cancer. 55: 1018-22. PMID 8253520 DOI: 10.1002/Ijc.2910550623 |
0.407 |
|
| 1994 |
Thiebaut F, Enns R, Howell SB. Cisplatin sensitivity correlates with its ability to cause cell cycle arrest via a wee1 kinase-dependent pathway in Schizosaccharomyces pombe. Journal of Cellular Physiology. 159: 506-14. PMID 8188765 DOI: 10.1002/Jcp.1041590315 |
0.301 |
|
| 1994 |
McClay EF, Albright KD, Jones JA, Christen RD, Howell SB. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines British Journal of Cancer. 70: 449-452. PMID 8080729 DOI: 10.1038/Bjc.1994.326 |
0.443 |
|
| 1994 |
Robbins KT, Vicario D, Seagren S, Weisman R, Pellitteri P, Kerber C, Orloff L, Los G, Howell SB. A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer. American Journal of Surgery. 168: 419-22. PMID 7977964 DOI: 10.1016/S0002-9610(05)80089-3 |
0.346 |
|
| 1994 |
Jamshidipour R, Pinho EB, Hom DK, Howell SB. Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell line. Cancer Chemotherapy and Pharmacology. 34: 484-90. PMID 7923559 DOI: 10.1007/Bf00685659 |
0.404 |
|
| 1994 |
Christen RD, Isonishi S, Jones JA, Jekunen AP, Hom DK, Kröning R, Gately DP, Thiebaut FB, Los G, Howell SB. Signaling and drug sensitivity. Cancer Metastasis Reviews. 13: 175-89. PMID 7923549 DOI: 10.1007/Bf00689635 |
0.33 |
|
| 1994 |
Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. British Journal of Cancer. 69: 299-306. PMID 7905279 DOI: 10.1038/Bjc.1994.55 |
0.442 |
|
| 1993 |
Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. British Journal of Cancer. 67: 1171-6. PMID 8512802 DOI: 10.1038/bjc.1993.221 |
0.32 |
|
| 1993 |
Jekunen AP, Shalinsky DR, Hom DK, Albright KD, Heath D, Howell SB. Modulation of cisplatin cytotoxicity by permeabilization of the plasma membrane by digitonin in vitro. Biochemical Pharmacology. 45: 2079-85. PMID 8512589 DOI: 10.1016/0006-2952(93)90019-S |
0.443 |
|
| 1993 |
Chamberlain MC, Khatibi S, Kim JC, Howell SB, Chatelut E, Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Archives of Neurology. 50: 261-4. PMID 8442704 DOI: 10.1001/Archneur.1993.00540030027009 |
0.3 |
|
| 1993 |
Mc Clay EF, Mc Clay ME, Albright KD, Jones JA, Christen RD, Alcaraz J, Howell SB. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation. Cancer. 72: 1914-8. PMID 8364868 DOI: 10.1002/1097-0142(19930915)72:6<1914::Aid-Cncr2820720620>3.0.Co;2-V |
0.406 |
|
| 1993 |
Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR, Howell SB. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. The Journal of Clinical Investigation. 92: 431-40. PMID 8100837 DOI: 10.1172/Jci116585 |
0.451 |
|
| 1993 |
Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon DJ, Howell SB. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 891-8. PMID 8098058 DOI: 10.1200/Jco.1993.11.5.891 |
0.3 |
|
| 1993 |
Shalinsky DR, Heath DD, Jekunen AP, Alcaraz JE, Howell SB. Selective modulation of vinblastine sensitivity by 1,9-dideoxyforskolin and related diterpenes in multidrug resistant tumour cells. British Journal of Cancer. 67: 471-9. PMID 8094975 DOI: 10.1038/Bjc.1993.89 |
0.444 |
|
| 1993 |
Shalinsky DR, Jekunen AP, Alcaraz JE, Christen RD, Kim S, Khatibi S, Howell SB. Regulation of initial vinblastine influx by P-glycoprotein. British Journal of Cancer. 67: 30-6. PMID 8094005 DOI: 10.1038/Bjc.1993.6 |
0.443 |
|
| 1992 |
Isonishi S, Jekunen AP, Hom DK, Eastman A, Edelstein PS, Thiebaut FB, Christen RD, Howell SB. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha. The Journal of Clinical Investigation. 90: 1436-42. PMID 1401076 DOI: 10.1172/Jci116010 |
0.349 |
|
| 1992 |
Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A, Howell SB. Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head & Neck. 14: 364-71. PMID 1399569 DOI: 10.1002/Hed.2880140505 |
0.306 |
|
| 1992 |
Christen RD, Shalinsky DR, Howell SB. Enhancement of the loss of multiple drug resistance by hydroxyurea. Seminars in Oncology. 19: 94-100. DOI: 10.5555/Uri:Pii:009377549290136O |
0.462 |
|
| 1991 |
Kirmani S, Lucas WE, Kim S, Goel R, McVey L, Morris J, Howell SB. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma Journal of Clinical Oncology. 9: 649-657. PMID 2066761 DOI: 10.1200/Jco.1991.9.4.649 |
0.302 |
|
| 1991 |
Isonishi S, Kirmani S, Kim S, Plaxe SC, Braly PS, McClay EF, Howell SB. Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole. Journal of the National Cancer Institute. 83: 621-6. PMID 2023280 DOI: 10.1093/Jnci/83.9.621 |
0.331 |
|
| 1991 |
Mann SC, Andrews PA, Howell SB. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells International Journal of Cancer. 48: 866-872. PMID 1713575 DOI: 10.1002/Ijc.2910480613 |
0.483 |
|
| 1991 |
Goel R, Howell SB. Modulation of the activity of cancer chemotherapeutic agents by dipyridamole Cancer Treatment and Research. 58: 19-44, 155. PMID 1683784 DOI: 10.1007/978-1-4615-3876-9_2 |
0.314 |
|
| 1990 |
Goel R, Sanga R, Howell SB. Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate. Cancer Chemotherapy and Pharmacology. 25: 167-72. PMID 2598406 DOI: 10.1007/Bf00689577 |
0.366 |
|
| 1990 |
McClay EF, Howell SB. A review: intraperitoneal cisplatin in the management of patients with ovarian cancer. Gynecologic Oncology. 36: 1-6. PMID 2403957 DOI: 10.1016/0090-8258(90)90099-7 |
0.32 |
|
| 1990 |
Andrews PA, Jones JA, Varki NM, Howell SB. Rapid emergence of acquired cis-diamminedichloroplatinum (II) resistance in an in vivo model of human ovarian carcinoma Cancer Communications. 2: 93-100. PMID 2372473 DOI: 10.3727/095535490820874641 |
0.451 |
|
| 1990 |
Mann SC, Andrews PA, Howell SB. Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells Cancer Chemotherapy and Pharmacology. 25: 236-240. PMID 2295111 DOI: 10.1007/BF00684878 |
0.339 |
|
| 1990 |
Christen RD, Hom DK, Porter DC, Andrews PA, MacLeod CL, Hafstrom L, Howell SB. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin Journal of Clinical Investigation. 86: 1632-1640. PMID 2243136 DOI: 10.1172/Jci114885 |
0.415 |
|
| 1990 |
Chan TC, Howell SB. Role of hypoxanthine and thymidine in determining methotrexate plus dipyridamole cytotoxicity. European Journal of Cancer (Oxford, England : 1990). 26: 907-11. PMID 2171601 DOI: 10.1016/0277-5379(90)90198-3 |
0.452 |
|
| 1990 |
Katz EJ, Vick JS, Kling KM, Andrews PA, Howell SB. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. European Journal of Cancer (Oxford, England : 1990). 26: 724-7. PMID 2168194 DOI: 10.1016/0277-5379(90)90127-F |
0.399 |
|
| 1990 |
Katz EJ, Andrews PA, Howell SB. The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells Cancer Communications. 2: 159-164. PMID 2114928 DOI: 10.3727/095535490820874515 |
0.43 |
|
| 1989 |
Goel R, Cleary SM, Horton C, Balis FM, Zimm S, Kirmani S, Howell SB. Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 262-9. PMID 2915241 DOI: 10.1200/Jco.1989.7.2.262 |
0.326 |
|
| 1989 |
Chan TC, Howell SB. Unexpected synergy between N-phosphonacetyl-L-aspartate and cytidine against human tumor cells. European Journal of Cancer & Clinical Oncology. 25: 721-7. PMID 2714348 DOI: 10.1016/0277-5379(89)90209-5 |
0.33 |
|
| 1989 |
Andrews PA, Murphy MP, Howell SB. Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells European Journal of Cancer and Clinical Oncology. 25: 619-625. PMID 2714338 DOI: 10.1016/0277-5379(89)90195-8 |
0.461 |
|
| 1989 |
Goel R, Cleary SM, Horton C, Kirmani S, Abramson I, Kelly C, Howell SB. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin Journal of the National Cancer Institute. 81: 1552-1560. PMID 2552131 DOI: 10.1093/Jnci/81.20.1552 |
0.302 |
|
| 1988 |
Andrews PA, Schiefer MA, Murphy MP, Howell SB. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chemico-Biological Interactions. 65: 51-8. PMID 3345573 DOI: 10.1016/0009-2797(88)90030-0 |
0.439 |
|
| 1988 |
Howell SB. Intraperitoneal chemotherapy for ovarian carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 6: 1673-5. PMID 3054001 DOI: 10.1200/Jco.1988.6.11.1673 |
0.377 |
|
| 1987 |
Markman M, Chan TC, Cleary S, Howell SB. Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole. Cancer Chemotherapy and Pharmacology. 19: 80-3. PMID 3815730 DOI: 10.1007/Bf00296262 |
0.321 |
|
| 1987 |
Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells Cancer Chemotherapy and Pharmacology. 19: 149-154. PMID 3568272 DOI: 10.1007/BF00254568 |
0.35 |
|
| 1987 |
Markman M, Howell SB. The intracavitary administration of cytarabine to patients with nonhematopoietic malignancies: An update Seminars in Oncology. 14: 116-120. DOI: 10.5555/Uri:Pii:0093775487900546 |
0.311 |
|
| 1986 |
Markman M, Cleary S, Howell SB. Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. European Journal of Cancer & Clinical Oncology. 21: 1015-8. PMID 4065175 DOI: 10.1016/0277-5379(85)90285-8 |
0.322 |
|
| 1986 |
Markman M, Howell SB. Daily intraperitoneal administration of cytarabine in a patient with peritoneal mesothelioma. Cancer Drug Delivery. 2: 285-9. PMID 4063951 DOI: 10.1089/Cdd.1985.2.285 |
0.322 |
|
| 1986 |
Howell SB, Pfeifle CE. Peritoneal access for intracavitary chemotherapy. Cancer Drug Delivery. 3: 157-61. PMID 3708538 DOI: 10.1089/Cdd.1986.3.157 |
0.341 |
|
| 1985 |
Andrews PA, Wung WE, Howell SB. A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate. Analytical Biochemistry. 143: 46-56. PMID 6099065 DOI: 10.1016/0003-2697(84)90556-6 |
0.304 |
|
| 1985 |
Markman M, Weiss R, Howell SB, Lucas WE. The intraoperative intraperitoneal administration of cisplatin: A case report Cancer Drug Delivery. 2: 87-90. PMID 4052929 DOI: 10.1089/Cdd.1985.2.87 |
0.303 |
|
| 1985 |
Markman M, Howell SB. Intrapericardial instillation of cisplatin in a patient with a large malignant effusion. Cancer Drug Delivery. 2: 49-52. PMID 4052925 DOI: 10.1089/Cdd.1985.2.49 |
0.326 |
|
| 1985 |
Markman M, Cleary S, Lucas WE, Howell SB. Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity Journal of Clinical Oncology. 3: 925-931. PMID 3894586 DOI: 10.1200/Jco.1985.3.7.925 |
0.337 |
|
| 1984 |
Howell SB, Pfeifle CE, Olshen RA. Intraperitoneal chemotherapy with melphalan. Annals of Internal Medicine. 101: 14-8. PMID 6732077 DOI: 10.7326/0003-4819-101-1-14 |
0.345 |
|
| 1984 |
Young JA, Howell SB, Green MR. Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine. Cancer Chemotherapy and Pharmacology. 12: 43-5. PMID 6690073 DOI: 10.1007/Bf00255908 |
0.323 |
|
| 1984 |
Markman M, Howell SB, Lucas WE, Pfeifle CE, Green MR. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2: 1321-6. PMID 6542584 DOI: 10.1200/Jco.1984.2.12.1321 |
0.332 |
|
| 1983 |
Wung WE, Howell SB. Modulation of plasma cyst(e)ine by cisplatin. European Journal of Cancer & Clinical Oncology. 19: 915-8. PMID 6576906 DOI: 10.1016/0277-5379(83)90057-3 |
0.308 |
|
| 1982 |
Taetle R, Howell SB, Giuliani FC, Koziol J, Koessler A. Comparison of the activity of doxorubicin analogues using colony-forming assays and human xenografts. Cancer. 50: 1455-61. PMID 6956427 DOI: 10.1002/1097-0142(19821015)50:8<1455::Aid-Cncr2820500803>3.0.Co;2-X |
0.308 |
|
| 1982 |
Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M. Intraperitoneal cisplatin with systemic thiosulfate protection. Annals of Internal Medicine. 97: 845-51. PMID 6890785 DOI: 10.7326/0003-4819-97-6-845 |
0.31 |
|
| 1982 |
Howell SB, Streifel JA, Pfeifle CE. Modulation of the cellular pharmacology and clinical toxicity of 1-beta-D-arabinofuranosylcytosine. Medical and Pediatric Oncology. 10: 81-91. PMID 6761570 DOI: 10.1002/Mpo.2950100710 |
0.314 |
|
| 1981 |
Howell SB, Wung WE, Taetle R, Hussain F, Romine JS. Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer. 48: 1281-9. PMID 7023652 DOI: 10.1002/1097-0142(19810915)48:6<1281::Aid-Cncr2820480603>3.0.Co;2-5 |
0.306 |
|
| 1981 |
Chu BCF, Howell SB, Fan CC. Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant l1210 cells Journal of the National Cancer Institute. 66: 121-124. PMID 6935452 DOI: 10.1093/Jnci/66.1.121 |
0.441 |
|
| 1980 |
Howell SB, Chu B, Mendelsohn J, Carson DA, Kung FH, Seegmiller JE. Thymidine as a chemotherapeutic agent: pharmacologic, cytokinetic, and biochemical studies in a patient with T-cell acute lymphocytic leukemia. Journal of the National Cancer Institute. 65: 277-84. PMID 6967527 DOI: 10.1093/Jnci/65.2.277 |
0.312 |
|
| 1980 |
Howell S, Taetle R, Mendelsohn J. Thymidine as a chemotherapeutic agent: sensitivity of normal human marrow, peripheral blood T cells, and acute nonlymphocytic leukemia Blood. 55: 505-510. DOI: 10.1182/Blood.V55.3.505.505 |
0.353 |
|
| Show low-probability matches. |
